Assignee
ADVAXIS INC
US·13 granted patents·27 pending applications·73 citations·filing 2013–2025
Top patents by PatentIndex Score
40 records- 0191US9907849B2Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancerADVAXIS INC·Filed 2015·Granted Mar 6, 2018·10 cites·15 claims
- 0290US11446369B2Compositions and methods comprising KLK3 or FOLH1 antigenADVAXIS INC·Filed 2019·Granted Sep 20, 2022·3 cites·16 claims
- 0390US10900044B2Listeria-based compositions comprising a peptide minigene expression system and methods of use thereofADVAXIS INC·Filed 2016·Granted Jan 26, 2021·6 cites·30 claims
- 0490US9650639B2Dual delivery system for heterologous antigensADVAXIS INC·Filed 2014·Granted May 16, 2017·11 cites·18 claims
- 0589US11702664B2Listeria-based compositions comprising a peptide minigene expression system and methods of use thereofADVAXIS INC·Filed 2020·Granted Jul 18, 2023·2 cites·18 claims
- 0688US11179339B2Compositions and methods for lyophilization of bacteria or listeria strainsADVAXIS INC·Filed 2018·Granted Nov 23, 2021·4 cites·26 claims
- 0788US9644212B2Dual delivery system for heterologous antigensADVAXIS INC·Filed 2014·Granted May 9, 2017·11 cites·10 claims
- 0887US10258679B2Recombinant Listeria vaccine strains and methods of producing the sameADVAXIS INC·Filed 2015·Granted Apr 16, 2019·6 cites·32 claims
- 0987US10064898B2Listeria-based adjuvantsADVAXIS INC·Filed 2016·Granted Sep 4, 2018·7 cites·14 claims
- 1086US10143734B2Biomarker directed multi-target immunotherapyADVAXIS INC·Filed 2015·Granted Dec 4, 2018·6 cites·29 claims
- 1180US10058599B2Suppressor cell function inhibition following Listeria vaccine treatmentADVAXIS INC·Filed 2013·Granted Aug 28, 2018·6 cites·14 claims
- 1274US2023357781A1Listeria-based compositions comprising a peptide minigene expression system and methods of use thereofADVAXIS INC·Filed 2023·Application pending·0 cites
- 1371US11897927B2Immunogenic compositions targeting recurrent cancer mutations and methods of use thereofADVAXIS INC·Filed 2017·Granted Feb 13, 2024·1 cites·74 claims
- 1470US12239738B2Compositions and methods for lyophilization of bacteria or listeria strainsADVAXIS INC·Filed 2021·Granted Mar 4, 2025·0 cites·20 claims
- 1564US2024124540A1Immunogenic compositions targeting recurrent cancer mutations and methods of use thereofADVAXIS INC·Filed 2023·Application pending·0 cites
- 1663US2025186350A1Compositions and methods for lyophilization of bacteria or listeria strainsADVAXIS INC·Filed 2025·Application pending·0 cites
- 1761US2015366955A9Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2014·Application pending·0 cites
- 1861US2014234370A1Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2014·Application pending·0 cites
- 1952US2019240303A1Recombinant listeria vaccine strains and methods of producing the sameADVAXIS INC·Filed 2019·Application pending·0 cites
- 2050US2015297702A1Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 2147US2016361401A1Compositions and methods for the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 2246US2021003558A1Compositions and methods for evaluating attenuation and infectivity of listeria strainsADVAXIS INC·Filed 2019·Application pending·0 cites
- 2346US2018185483A1Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancerADVAXIS INC·Filed 2018·Application pending·0 cites
- 2444US2018265879A1Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strainADVAXIS INC·Filed 2016·Application pending·0 cites
- 2544US2017204361A1Manufacturing device and process for personalized delivery vector-based immunotherapyADVAXIS INC·Filed 2016·Application pending·0 cites
- 2643US2019248856A1Listeria-Based Immunogenic Compositions Comprising Wilms Tumor Protein Antigens And Methods Of Use ThereofADVAXIS INC·Filed 2017·Application pending·0 cites
- 2743US2018325964A1Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strainADVAXIS INC·Filed 2016·Application pending·0 cites
- 2843US2017368157A1Combination Of Listeria-Based Vaccine With Anti-OX40 Or Anti-GITR AntibodiesADVAXIS INC·Filed 2015·Application pending·0 cites
- 2943US2016220652A1Methods of using recombinant listeria vaccine strains in disease immunotherapyADVAXIS INC·Filed 2016·Application pending·0 cites
- 3043US2021239681A1Compositions and methods for evaluating potency of listeria-based immunotherapeuticsADVAXIS INC·Filed 2019·Application pending·0 cites
- 3141US2018104284A1Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use ThereofADVAXIS INC·Filed 2016·Application pending·0 cites
- 3241US2018064765A1Listeria-based immunogenic compositions for eliciting anti-tumor responsesADVAXIS INC·Filed 2015·Application pending·0 cites
- 3340US2017246273A1Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereofADVAXIS INC·Filed 2015·Application pending·0 cites
- 3440US2019032064A1Personalized Delivery Vector-Based Immunotherapy and Uses ThereofADVAXIS INC·Filed 2017·Application pending·0 cites
- 3540US2021177955A1Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereofADVAXIS INC·Filed 2018·Application pending·0 cites
- 3640US2020061167A1Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodiesADVAXIS INC·Filed 2017·Application pending·0 cites
- 3737US2018305702A1Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And TreatmentADVAXIS INC·Filed 2016·Application pending·0 cites
- 3835US2018280487A1Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapyADVAXIS INC·Filed 2016·Application pending·0 cites
- 3934US2019381160A1Personalized delivery vector-based immunotherapy and uses thereofADVAXIS INC·Filed 2016·Application pending·0 cites
- 4032US2018360940A1Listeria-based immunotherapy and methods of use thereofADVAXIS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ADVAXIS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →